Reflections One Year Post-IPO

June 26, 2014
Tim Mayleben
President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More

Posted In: Company News

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

May 7, 2014
Tim Mayleben
President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the recent spate of biotech IPOs belies the earlier struggle to finance trials and product development. I was joined by fellow biotech CEOs, Jeff Abbey of Argos and Scott Koenig of MacroGenics, for an engaging and… Read More